Compare iShares MSCI South Korea ETF (EWY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Viatris Inc — how do they compare? iShares MSCI South Korea ETF trades at $163.2, while Viatris Inc trades at $17.35 (market cap $19.44B). The key difference: Viatris Inc pays a 2.88% dividend while iShares MSCI South Korea ETF pays none, and Viatris Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals.
| EWY | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $17.39 |
52-Week Low | $70.65 | $8.74 |
Market Cap | — | $19.44B |
Enterprise Value | — | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $163.67, down 7.52% with significant volatility driven by its heavy concentration in South Korean semiconductor giants Samsung and SK Hynix. The ETF has entered bear market territory, reflecting global tech sector pressures and foreign investor selling. Technical indicators show bearish momentum with RSI near oversold levels at 28, while support sits at $157. Recent news highlights the Kospi Index's 21% decline from YTD highs, creating both risk and potential opportunity.
The outlook remains challenged by semiconductor cycle volatility and concentrated exposure, but long-term AI demand fundamentals provide potential upside. Key risks include single-stock concentration, foreign capital flows, and global tech sentiment shifts. Investors should weigh near-term volatility against structural semiconductor growth drivers.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
